Last updated: October 16, 2026
Yervoy, Bristol Myers Squibb’s ipilimumab, is a fully human monoclonal antibody targeting CTLA-4. Its commercial trajectory has shifted from melanoma monotherapy to a combination-based immuno-oncology platform, mainly with Opdivo. Yervoy generated approximately $2.5 billion in global revenue in 2023, but its long-term growth depends on combination regimens, new tumor types, and continued protection against biosimilar competition. The reference product’s U.S. biologic exclusivity expired in 2023, while patent barriers and manufacturing complexity remain more important than regulatory exclusivity.
What is Yervoy and how does it work?
Yervoy is ipilimumab, an IgG1 monoclonal antibody that blocks CTLA-4, an immune checkpoint receptor on T cells. CTLA-4 inhibition increases T-cell activation and supports an immune response against tumor cells.
The FDA initially approved Yervoy in March 2011 for unresectable or metastatic melanoma. The product later expanded into adjuvant melanoma and combination treatment across several solid tumors.
| Attribute |
Yervoy profile |
| Active ingredient |
Ipilimumab |
| Developer |
Medarex |
| Current commercial owner |
Bristol Myers Squibb |
| Mechanism |
CTLA-4 immune checkpoint inhibition |
| Dosage form |
Intravenous infusion |
| Initial FDA approval |
March 25, 2011 |
| Reference application |
BLA 125377 |
| Primary commercial partner |
Opdivo, nivolumab |
| Regulatory category |
Biologic |
| Orange Book status |
Not listed as a conventional small-molecule product |
| Relevant FDA reference |
Purple Book and BLA records |
Bristol Myers Squibb acquired Medarex in 2009 for approximately $2.4 billion, obtaining ipilimumab and the underlying CTLA-4 development platform before Yervoy’s approval.[1]
What indications does Yervoy have?
Yervoy’s commercial value comes from its role in combination immunotherapy rather than from monotherapy alone.
FDA-approved uses
The FDA label covers Yervoy in several settings:
- Unresectable or metastatic melanoma
- Adjuvant treatment of melanoma with pathologic involvement of regional lymph nodes greater than 1 millimeter or metastatic disease following complete resection
- Advanced renal cell carcinoma in combination with Opdivo
- Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient tumors, in combination with Opdivo
- Hepatocellular carcinoma after prior sorafenib, in combination with Opdivo
- Metastatic non-small-cell lung cancer in combination with Opdivo and platinum-doublet chemotherapy
- Unresectable malignant pleural mesothelioma in combination with Opdivo
- Esophageal squamous cell carcinoma in combination with Opdivo
- Certain gastric, gastroesophageal junction, and esophageal adenocarcinomas in combination with Opdivo and chemotherapy
The label and dosing schedules differ substantially by tumor type. The most commercially important pattern is a limited number of Yervoy doses combined with repeated Opdivo treatment. This makes Yervoy a strategic component of a broader Bristol Myers Squibb franchise rather than a stand-alone chronic therapy.[2]
How has Yervoy revenue changed?
Yervoy revenue has remained durable but has not followed the rapid growth pattern of newer checkpoint products. Public company reporting indicates the following approximate trajectory:
| Fiscal year |
Yervoy global revenue |
Year-over-year direction |
| 2021 |
Approximately $2.4 billion |
Stable to modest growth |
| 2022 |
Approximately $2.3 billion |
Broadly stable |
| 2023 |
Approximately $2.5 billion |
Growth, supported by combination use |
Bristol Myers Squibb reported Yervoy sales of approximately $2.45 billion in 2023.[3] The product’s revenue base is significant, but it is materially smaller than Opdivo, which generated roughly $9 billion in 2023. Yervoy therefore contributes less direct revenue than Opdivo while helping protect and expand the value of the combination franchise.
What drives Yervoy revenue?
Yervoy revenue is driven by four factors:
- Greater use of Opdivo-Yervoy combinations in renal cell carcinoma, lung cancer, mesothelioma, hepatocellular carcinoma, and gastrointestinal cancers.
- Earlier-line treatment, where patient populations are larger.
- Weight-based or fixed-dose regimen economics and site-of-care purchasing.
- Continued international access and reimbursement for combination immunotherapy.
Monotherapy melanoma demand is no longer the primary growth engine. The product’s commercial position depends on physician adoption of dual checkpoint blockade despite higher toxicity and treatment-management requirements.
What is the competitive landscape for Yervoy?
Yervoy competes in a crowded checkpoint-inhibitor market. Its closest competitive products are PD-1 and PD-L1 inhibitors, which often have broader use, simpler administration, and lower toxicity than CTLA-4 combinations.
| Product |
Company |
Target |
Main competitive role |
| Yervoy |
Bristol Myers Squibb |
CTLA-4 |
Combination intensification |
| Opdivo |
Bristol Myers Squibb |
PD-1 |
Primary combination partner |
| Keytruda |
Merck |
PD-1 |
Broad first-line immunotherapy competitor |
| Tecentriq |
Roche |
PD-L1 |
Lung, liver, and other solid tumors |
| Imfinzi |
AstraZeneca |
PD-L1 |
Lung, liver, and gastrointestinal indications |
| Libtayo |
Regeneron/Sanofi |
PD-1 |
Skin cancer and selected solid tumors |
| Imjudo |
AstraZeneca |
CTLA-4 |
Direct CTLA-4 combination competitor |
Keytruda is the principal commercial competitor because Merck has built extensive first-line treatment coverage across solid tumors. AstraZeneca’s Imjudo provides the most direct CTLA-4 comparison in liver and lung cancer. The competitive question is usually not Yervoy versus another CTLA-4 antibody alone. It is whether a Yervoy-containing regimen produces sufficient survival benefit to justify increased immune-related adverse events compared with PD-1 or PD-L1 monotherapy.
How strong is the Yervoy patent estate?
Yervoy’s U.S. regulatory exclusivity is finished, but biologic competition is still constrained by patent scope, clinical-development requirements, manufacturing difficulty, and commercial scale.
U.S. exclusivity and patent position
The FDA granted Yervoy 12 years of reference-product biologic exclusivity under the Biologics Price Competition and Innovation Act. That period ran from the product’s first licensure in 2011 and expired in March 2023.[4]
Unlike small-molecule drugs, biologics do not receive a conventional Orange Book listing with a standardized set of patents and expiration dates. Yervoy’s relevant rights must be assessed through patent prosecution records, litigation records, licensing history, and the FDA Purple Book.
The principal patent categories include:
- Anti-CTLA-4 antibody composition claims
- Antibody sequence and binding claims
- Methods of treating melanoma and other cancers
- Combination treatment with PD-1 inhibition
- Dosing and treatment-regimen claims
- Cell-line, purification, and manufacturing claims
Medarex and Bristol Myers Squibb built the early ipilimumab estate around anti-CTLA-4 antibodies and cancer treatment methods. Some early composition and foundational platform rights have expired or are approaching the end of their terms. Later-filed method-of-use, dosing, and combination patents can extend protection for specific uses without creating a complete monopoly over every ipilimumab biosimilar application.
What patent expiration dates matter?
The economically relevant patent dates are not limited to one “Yervoy patent expiry” date. The estate consists of different patent families with different priority dates, terminal disclaimers, patent-term adjustments, and geographic scope.
The practical timeline is:
| Event |
Date or status |
| FDA approval of Yervoy |
March 25, 2011 |
| U.S. reference-product exclusivity |
Expired in March 2023 |
| Early platform and antibody patents |
Some expired; others require family-level review |
| Later method-of-use and combination patents |
May extend into the mid-to-late 2020s, depending on claim and jurisdiction |
| Biosimilar filing pathway |
Legally available after reference-product exclusivity |
| Approved U.S. Yervoy biosimilar |
None identified in the cited FDA materials through the source period |
A patent-by-patent freedom-to-operate conclusion cannot be drawn from the BLA alone. The most significant commercial question is whether a biosimilar applicant can launch around remaining method-of-use and combination claims while supplying the same active antibody for unprotected indications.
What is the Orange Book and Purple Book status of Yervoy?
Yervoy does not have the standard Orange Book profile associated with a small-molecule drug such as Keytruda is also a biologic? Correction, Keytruda biologic too. Biologics are generally tracked through the FDA Purple Book, not through Orange Book patent listings.
The Purple Book identifies licensed biological products and reference products relevant to biosimilar substitution. It does not provide the same patent-certification framework used for an Abbreviated New Drug Application under Hatch-Waxman.
This distinction matters because Yervoy biosimilar challengers do not use the same Paragraph IV process that applies to generic drugs. A biosimilar applicant follows the BPCIA pathway and may participate in the statutory patent-information exchange and litigation process.
Are there Paragraph IV challenges to Yervoy?
No conventional Paragraph IV challenge applies to Yervoy because it is a biologic. A biosimilar applicant does not file an ANDA and does not certify against Orange Book patents.
The relevant alternatives are:
- A 351(k) biosimilar application
- Patent-information exchange under the BPCIA
- Declaratory judgment or patent litigation
- Commercial launch after resolution of asserted patents
- Interchangeability designation, if supported by the application and FDA review
The absence of Paragraph IV litigation does not mean the product is free from patent risk. It means the litigation framework differs from that used for generic tablets, capsules, and injectable small molecules.
What biosimilar risks exist for Yervoy?
Yervoy faces eventual biosimilar risk, but the timing is likely to be slower than the loss of exclusivity for a conventional injectable generic.
Regulatory barriers
An ipilimumab biosimilar developer must demonstrate high similarity to the reference product, with no clinically meaningful differences in safety, purity, and potency. The developer must also establish an appropriate analytical and clinical package under the FDA’s 351(k) pathway.
Manufacturing barriers
Ipilimumab is a complex monoclonal antibody. Manufacturing barriers include:
- Mammalian-cell expression
- Control of glycosylation and product-related variants
- Viral clearance and contamination controls
- Process validation
- Comparability after manufacturing changes
- Stability and release testing
- Commercial-scale supply reliability
The cost and time required to develop a biosimilar can limit the number of viable challengers. A biosimilar company also needs sufficient oncology market access to support the investment, particularly because Yervoy is frequently administered as part of a combination regimen controlled by Bristol Myers Squibb’s Opdivo franchise.
Commercial barriers
Yervoy demand is concentrated in institutional oncology channels. Hospitals and oncology practices may adopt a biosimilar if price discounts are substantial, but switching can be more difficult when:
- Yervoy is used in a branded combination protocol
- Treatment pathways are tied to Opdivo reimbursement
- Physicians prioritize established supply and pharmacovigilance systems
- Only selected indications are commercially attractive
- Payers require regimen-level, rather than product-level, contracting
The first biosimilar may obtain a meaningful discount without immediately replacing the reference product. Interchangeability, payer contracts, and physician confidence will determine the speed of substitution.
What licensing deals and ownership history affect Yervoy?
Yervoy originated with Medarex, which developed CTLA-4 antibodies and advanced ipilimumab into clinical development. Bristol Myers Squibb acquired Medarex in 2009. That transaction consolidated control of the asset before FDA approval.
The ownership history differs from Opdivo. Opdivo was developed through Bristol Myers Squibb’s relationship with Ono Pharmaceutical, including licensing and commercialization rights in territories outside Japan. Yervoy’s core ownership is associated with the Medarex acquisition rather than the Ono collaboration.
This distinction matters for revenue attribution, royalty obligations, and control of future combination development. Bristol Myers Squibb controls both Yervoy and Opdivo in most major markets, allowing it to design, register, price, and market the combination as an integrated franchise.
What litigation and settlement risks affect Yervoy?
Yervoy’s principal legal risks are likely to arise from:
- Biosimilar patent litigation
- Patent validity challenges involving antibody and method claims
- Inventorship and ownership disputes
- Manufacturing-process disputes
- Combination-regimen claims involving Yervoy and Opdivo
- Antitrust or pricing litigation involving biologic contracting
A public settlement involving a future biosimilar could establish an authorized or licensed launch date before the expiration of every potentially relevant patent. That outcome would reduce litigation uncertainty but could accelerate revenue erosion.
The absence of a traditional generic launch date makes scenario analysis more useful than a single patent-expiry date.
What generic or biosimilar launch scenarios exist?
Early biosimilar entry
A biosimilar enters after resolving or avoiding key composition and method claims. Revenue declines first in price-sensitive hospital accounts and lower-margin international markets.
Staged indication entry
The biosimilar launches for indications with fewer enforceable method-of-use barriers, while Bristol Myers Squibb retains protected or commercially dominant combination uses.
Delayed entry
Patent litigation, manufacturing investment, or limited commercial interest delays launch into the late 2020s or beyond. Yervoy retains a larger share of the market, but revenue still faces pressure from competitive regimens.
Rapid substitution
Multiple biosimilars enter within a short period. Payers impose mandatory or preferred use, producing sharper price erosion. This scenario is less likely than rapid generic substitution for a small molecule because of biologic manufacturing and interchangeability requirements.
How does Yervoy compare with Opdivo and Keytruda?
| Factor |
Yervoy |
Opdivo |
Keytruda |
| Target |
CTLA-4 |
PD-1 |
PD-1 |
| Company |
Bristol Myers Squibb |
Bristol Myers Squibb |
Merck |
| Primary role |
Combination intensification |
Broad monotherapy and combination backbone |
Broad monotherapy and combination backbone |
| Revenue scale |
Approximately $2.5 billion in 2023 |
Approximately $9 billion in 2023 |
Much larger than Yervoy, with broad global use |
| Toxicity |
Higher in combination regimens |
Generally lower than CTLA-4 combinations |
Generally lower than CTLA-4 combinations |
| Biosimilar risk |
Long-term, developing |
Long-term, developing |
Long-term, developing |
| Commercial dependency |
Strongly linked to Opdivo |
Broad standalone franchise |
Broad standalone franchise |
Yervoy has a narrower but strategically important position. Opdivo and Keytruda compete for the core PD-1 market, while Yervoy is used to increase treatment intensity in selected patients.
What is the financial outlook for Yervoy?
Yervoy is likely to remain a multibillion-dollar product during the medium term, but its revenue profile is mature.
The main positive factors are:
- Expansion of dual immunotherapy into earlier treatment lines
- Increased use in renal cell carcinoma and lung cancer
- New combination approvals
- Continued value of the Opdivo-Yervoy franchise
- Limited near-term biosimilar competition
The main negative factors are:
- Mature melanoma demand
- Competition from Keytruda-based regimens
- Higher toxicity and treatment discontinuation
- Payer pressure on combination cost
- Eventual biosimilar pricing
- Potential migration toward PD-1 or PD-L1 monotherapy
- Dependence on Opdivo’s clinical and commercial performance
Yervoy should be valued as a franchise-support product rather than as a stand-alone growth asset. Its economic contribution includes direct drug sales, protection of Opdivo combination positioning, and participation in high-value oncology protocols.
Key Takeaways
- Yervoy is ipilimumab, a CTLA-4 antibody owned by Bristol Myers Squibb.
- FDA approval began in March 2011, and 12-year U.S. biologic exclusivity expired in March 2023.
- Yervoy generated approximately $2.5 billion in global revenue in 2023.
- Its commercial role has shifted from melanoma monotherapy to combination treatment, principally with Opdivo.
- Yervoy is tracked through the biologic framework and Purple Book, not a conventional Orange Book listing.
- Paragraph IV litigation does not apply because Yervoy is a biologic rather than an ANDA-eligible small molecule.
- The main future threat is biosimilar competition, constrained by manufacturing complexity, patent claims, regulatory requirements, and combination-regimen economics.
- Yervoy’s patent risk is family-specific. Composition, method-of-use, dosing, combination, and manufacturing patents can have different expiration dates.
- The product’s financial trajectory is mature but durable, with revenue dependent on new combination indications and Opdivo franchise performance.
- The most likely erosion pattern is staged biosimilar entry rather than an immediate generic-style collapse.
FAQs
When did Yervoy lose FDA biologic exclusivity?
Yervoy’s 12-year U.S. reference-product biologic exclusivity expired in March 2023, based on its March 25, 2011, first licensure date.
Can a biosimilar replace Yervoy automatically at the pharmacy?
No. Yervoy is administered by intravenous infusion in institutional settings. Automatic substitution depends on FDA interchangeability status, state law, payer policy, and provider or health-system protocols.
Is Yervoy more vulnerable to biosimilar erosion than Opdivo?
Yervoy may be more vulnerable in principle because its biologic exclusivity has expired and its revenue is concentrated in combination use. In practice, the timing depends on biosimilar development, patent litigation, and whether hospitals adopt an alternative within Opdivo-based protocols.
What is the main competitor to Yervoy?
The principal direct competitor is Imjudo, tremelimumab, another CTLA-4 antibody. Keytruda and other PD-1 or PD-L1 products are the larger commercial competitors because they compete against the treatment regimens in which Yervoy is used.
Does Yervoy have an Orange Book patent listing?
No conventional Orange Book listing applies because Yervoy is a biologic. Patent and biosimilar information must be evaluated through the FDA Purple Book, patent records, regulatory filings, and BPCIA litigation.
References
- Bristol Myers Squibb. (2009). Bristol-Myers Squibb to acquire Medarex.
- U.S. Food and Drug Administration. (2024). Yervoy (ipilimumab) prescribing information.
- Bristol Myers Squibb. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
